Pedmark® reduced the risk of cisplatin-induced ototoxicity in pediatric patients with hepatoblastoma, seen in a Turkish compassionate use treatment protocol

Cabi, Emel ÜnalTacyıldız, NurdanAtaseven, EdaSivrice, Ayşe ÇiğdemSevinir, BetülBrock, PenelopeBhattacharya, AnanyaMorgan, AllisonBaskin-Bey, EdwinaAltınel, Serdar2024-11-182024-11-182023-11-011545-5009https://hdl.handle.net/11452/48018eninfo:eu-repo/semantics/closedAccessOncologyHematologyPediatricsPedmark® reduced the risk of cisplatin-induced ototoxicity in pediatric patients with hepatoblastoma, seen in a Turkish compassionate use treatment protocolMeeting Abstract001183650902354S572S57370Supplement 8